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Abstract
Background: Cyclooxygenase-2 (COX-2) is induced under inflammatory conditions, and prostaglandin E2 (PGE2) is
one of the products of COX activity. PGE2 has pleiotropic actions depending on the activation of specific E-type
prostanoid EP1-4 receptors. We investigated the involvement of PGE2 and EP receptors in glial activation in
response to an inflammatory challenge induced by LPS.
Methods: Cultures of mouse microglia or astroglia cells were treated with LPS in the presence or absence of COX-2
inhibitors, and the production of PGE2 was measured by ELISA. Cells were treated with PGE2, and the effect on
LPS-induced expression of TNF-α messenger RNA (mRNA) and protein was studied in the presence or absence of
drug antagonists of the four EP receptors. EP receptor expression and the effects of EP2 and EP4 agonists and
antagonists were studied at different time points after LPS.
Results: PGE2 production after LPS was COX-2-dependent. PGE2 reduced the glial production of TNF-α after LPS.
Microglia expressed higher levels of EP4 and EP2 mRNA than astroglia. Activation of EP4 or EP2 receptors with
selective drug agonists attenuated LPS-induced TNF-α in microglia. However, only antagonizing EP4 prevented
the PGE2 effect demonstrating that EP4 was the main target of PGE2 in naïve microglia. Moreover, the relative
expression of EP receptors changed during the course of classical microglial activation since EP4 expression was
strongly depressed while EP2 increased 24 h after LPS and was detected in nuclear/peri-nuclear locations. EP2
regulated the expression of iNOS, NADPH oxidase-2, and vascular endothelial growth factor. NADPH oxidase-2
and iNOS activities require the oxidation of NADPH, and the pentose phosphate pathway is a main source of
NADPH. LPS increased the mRNA expression of the rate-limiting enzyme of the pentose pathway glucose-6-
phosphate dehydrogenase, and EP2 activity was involved in this effect.
Conclusions: These results show that while selective activation of EP4 or EP2 exerts anti-inflammatory actions,
EP4 is the main target of PGE2 in naïve microglia. The level of EP receptor expression changes from naïve to
primed microglia where the COX-2/PGE2/EP2 axis modulates important adaptive metabolic changes.
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Background
Cyclooxygenase-2 (COX-2) is induced in brain cells
under inflammatory conditions, but the role of COX-2
in the inflammatory response is very complex because it
participates in different stages from initiation to reso-
lution. While COX-2 is associated to inflammation and
COX-2 inhibitors have anti-inflammatory properties,
COX-2-deficient mice show exacerbated inflammation,
leukocyte infiltration, and blood-brain barrier damage
after exposure to the bacterial lipopolysaccharide (LPS),
while these effects are attenuated in COX-1-deficient
mice [1–5]. The COX pathway generates multifunctional
vasoactive prostanoids in a cell type-dependent manner
depending on the relative expression of constitutive
COX-1 and inducible COX-2 and on the preferential
coupling of COX isoforms with prostanoid synthases [6].
Prostaglandin E2 (PGE2) is a main product of COX-2 ac-
tivity in glial cells under inflammatory conditions [7].
PGE2 exerts pro- (e.g., [8–10]) and anti-inflammatory
(e.g., [11–13]) actions likely due to its involvement in
regulating the onset, course, magnitude, and duration of
the inflammatory response [14]. Furthermore, PGE2
plays crucial actions in regulating immune responses
[15].
PGE2 exerts pleiotropic effects depending on signaling
through four distinct E-type prostanoid (EP) receptors:
EP1–4 [16]. EP receptors are G-protein-coupled plasma
membrane receptors activating different signal transduc-
tion pathways [17]. Therefore, the type of response to
PGE2 depends on the cell/tissue-specific expression of
the EP receptors. EP4 selective agonists decrease LPS-
induced pro-inflammatory gene expression in mouse
microglia [18]. In cultured rat microglial cells exposed to
LPS and IFN-γ, PGE2 induces complex effects, including
the up-regulation of COX-2, iNOS, IL-6, and IL-1β but
down-regulation of TNF-α, and all these effects were at-
tributed to EP2 [19]. Here, we investigated how COX-2,
PGE2, and EP receptors affected the dynamic response




Primary cell cultures of glial cells were obtained from
postnatal C57BL/6J mice. Glial cell cultures enriched in
astrocytes were prepared from the cerebral cortex of 1-
to 2-day-old mice, as previously described [20, 21], with
minor modifications. In brief, the cells were maintained
at 37 °C in a humidified atmosphere of 5% CO2-95% air
in complete culture medium: DMEM:F-12 nutrient (1:1)
(Gibco-BRL), supplemented with 10% fetal bovine serum
(FBS; Gibco-BRL) and 4 mL/L of a mixture of penicillin/
streptomycin 10,000 U/10,000 μg/mL (Gibco-BRL). Cells
were subcultured to obtain purified astroglia cultures, as
follows: at confluence after 8–10 days in vitro, cells were
treated with 4 μM of the antimitotic cytosine arabinoside
(Ara-C, Sigma-Aldrich) for 2 days to eliminate dividing
cells, i.e., mostly microglia and progenitors; then, flasks
were shaken overnight, and the remaining astrocyte ad-
herent monolayer was detached with trypsin 0.0125%/
EDTA 1 mM and seeded at 10 × 104 cells/mL with an
incubation medium (as above) on polylysine-coated
plates. Purified astrocytes were treated when cells
reached confluence at 4 days after subculturing. FBS was
reduced to 1% for 16 h prior to treatments. Astrocyte
cultures contained only 2% of contaminating microglia
cells [7, 21]. Highly pure microglia cell cultures were
prepared following the mild trypsinization method de-
scribed previously [22], with minor modifications.
Briefly, mixed glia cultures were maintained 19 days in
vitro, performing a subculture to increase the efficiency
at day 8, as described above. Astrocyte monolayer was
discarded and bottom microglia was kept, as follows: the
cells were incubated for 30 min with trypsin 0.0625%/
EDTA 1 mM causing the detachment of an upper layer
of astrocytes in one piece. The remained attached micro-
glia was maintained in a culture medium solution con-
taining half medium of mixed glia cultures and half new
culture medium. Purified microglia was treated 1 day
after purification with reduction of FBS to 1% 1 h prior
to treatments. Microglia culture purity was determined
by counting the number of isolectin-positive cells out of
the total cell nuclei number per area in four different
areas (×20 objective) in four independent microglia cul-
tures. The mean ± SD percentage of microglial cells was
97 ± 2.8% (see Additional file 1: Figure S1).
Primary cultures of macrophages were obtained from
the bone marrow of adult (3 months old) male C57BL/6
mice. The cells were cultured in DMEM containing 10%
FBS, penicillin/streptomycin as above, and 30% L-Cell
medium obtained from the L929 cell line. After 6 days
in culture, macrophages were replated (250,000 cells/
mL). The following day, the medium was replaced by
DMEM with 1% FBS, and cells were treated 1 hour later.
Drug treatments
The cells were exposed to LPS (Escherichia coli 055:B5)
(Sigma-Aldrich, St. Louis, MO, USA) (10 ng/mL, unless
otherwise stated). The following COX-2 inhibitors were
used: 3 μM N-[cyclohexyloxy-4-nitrophenyl] methane-
sulfonamide (NS-398; Tocris Bioscience, Ellisville, MO,
USA), 10 μM celecoxib and 2,5-dimethyl-celecoxib
inactive analog (Sigma-Aldrich), 10 nM sc-791-COX2
Inhibitor II (Calbiochem, EMD Millipore, Merck KGaA,
Darmstadt, Germany), and 10 nM CAY 10404 (Cayman
Chemical Co., Ann Arbor, MI, USA). Drug inhibitors
were dissolved in dimethyl sulfoxide (DMSO). Prosta-
glandin E2 (PGE2) (1.4–11.3 nM in ethanol) was from
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Sigma-Aldrich. The EP4 agonist ONO-4819 (100 nM in
ethanol) and EP2 agonist butaprost (1 μM in DMSO)
were from Cayman Chemical Co. Selective EP receptor
antagonists (Tocris Bioscience) were used: EP1 antagon-
ist (SC 51089, 5 μM), EP2 antagonist (PF 04418948,
1 μM), EP3 antagonist (L-798,106, 0.5 μM) and EP4
antagonist (GW 627368, 1 μM). EP antagonists were dis-
solved in DMSO. Drugs were diluted in phosphate-buffered
saline (PBS). The final ethanol or DMSO concentration did
not exceed 0.0005 or 0.00015%, respectively. Corresponding
vehicles were used in all experiments to check for non-
specific effects. The above drug concentrations correspond
to the final concentration in the culture medium. Drug
concentrations were chosen based on the half maximal in-
hibitory concentration, literature reports, and preliminary
experiments carried out in primary cultures of macro-
phages and microglia (see Additional file 2: Figure S2).
Western blotting
Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer containing protease inhibitors. Five micro-
grams of protein were resolved by SDS-PAGE, and the
proteins were transferred to polyvinylidene difluoride
membranes. Rabbit polyclonal antibodies were used
against vascular endothelial growth factor-A (VEGFA)
(#ab46154, Abcam) diluted 1:500; NADPH oxidase 2
(NOX2/gp91phox) (#ab129068, Abcam) diluted 1:500;
and EP2 receptor (#APR-064, kindly provided by Alomone
Labs, Jerusalem, Israel) diluted 1:1000. Mouse monoclonal
antibodies against β-tubulin (#T4026, Sigma, St. Louis,
MO, USA) (1:10,000) or glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH, #CSA-335, Assay Designs, Ann
Arbor, USA) (1:5000), were used as protein gel loading
controls. Antibodies were diluted in Tris-buffered saline
containing 0.5% Tween-20 and were incubated overnight
at 4 °C, followed by horseradish peroxidase-conjugated
secondary antibodies (Amersham Biosciences, Piscataway,
NJ, USA) (1:2000) 1 h at RT. The blots were developed
with a chemiluminescent substrate (Luminol 250 mM,
Sigma). Band intensity was quantified by densitometry
(Quantity One, Bio-Rad, Hercules, CA, USA).
Nuclear extracts
Nuclear extracts were prepared from macrophage cul-
tures. The cells we collected in Hepes buffer with prote-
ase and phosphatase inhibitors and were centrifuged at
300×g for 5 min at 4 °C. The pellet was suspended in
hypotonic buffer (20 mM Hepes pH 7.5, 5 mM NaF, and
10 mM Na2MoO4). After 15 min at 4 °C, non-ionic de-
tergent was added (50 μL Igepal 10%/mL), mixed and
centrifuged at 12,000×g for 30 min. The pellet was sus-
pended in 30 μL RIPA buffer. Twelve micrograms of nu-
clear protein was run in 10% polyacrylamide gels, and
EP2 expression was analyzed by Western blotting as
above. As gel loading control for nuclear protein, we
used a mouse monoclonal antibody against TATA-
binding protein (TBP, #ab51841, Abcam) diluted 1:500.
Immunocytochemistry
The cells were seeded on polylysine-coated coverslips.
The cells were fixed in 4% paraformaldehyde for 20 min,
permeabilized with 0.2% Triton X-100 (Sigma) in PBS
for 10 min, blocked with 3% goat serum in PBS for 1 h
and incubated overnight at 4 °C with the primary rabbit
antibodies against the EP2 (#APR-064, kindly provided
by Alomone Labs) (1:100) and EP4 (#ab93486, Abcam,
Cambridge, UK) (1:200) receptors. The next day, cells
were washed and incubated with green fluorescence
Alexa Fluor® 488 dye-labeled goat anti-rabbit IgG anti-
body (#A11070, Invitrogen, Glasgow, UK) for 1 h at
room temperature. ToPro®-3 Iodide (T3605, Invitrogen)
(1:1000) stained was performed to visualize the cell
nuclei. The coverslips were mounted onto microscope
slides using Fluormount-G® (Southern Biotech,
Birmingham, AL, USA). Images were obtained with a
laser confocal microscope (TCS SPE, Leica Microsys-
tems, Wetzlar, Germany).
Real-time RT-PCR
Total RNA was extracted using Purelink RNA Kit (Invi-
trogen). RNA quantity and purity were assessed in a ND-
1000 micro-spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). One hundred fifty micrograms of
total RNA was reverse-transcribed using a mixture of ran-
dom primers (High Capacity cDNA Reverse Transcription
kit, Applied Biosystems, Foster City, CA, USA). Real-time
quantitative RT-PCR analysis was carried out by SYBR
green I dye detection (#11761500, Invitrogen) or Taqman
probes (#4304437, Life Technology, Carlsbad, CA, USA)
using the iCycler iQTM Multicolor Real-Time Detection
System (Bio-Rad). PCR primers were designed with
Primer-Blast software of PubMed to bridge the exon-
intron boundaries within the gene of interest to exclude
amplification of contaminating genomic DNA. Primers
(Table 1) were purchased from IDT (Conda, Spain) and
Invitrogen. Optimized thermal cycling conditions for
SYBR green assays were as follows 2 min at 50 °C, 10 min
at 95 °C followed by 40 cycles of 15 sec at 95 °C and
1 min at 60 °C and finally 1 min at 95 °C, 1 min and 10 s
at 55 °C. For Taqman system, the primers are listed in
Table 1 and the qPCR conditions were 10 min at 95 °C
followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C
and finally 30 s at 40 °C. Data were collected after each
cycle and were graphically displayed (iCycler iQTM
Real-time Detection System Software, version 3.1, Bio-
Rad). Melt curves were performed upon completion of
the cycles to ensure absence of non-specific products.
Quantification was performed by normalizing cycle
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threshold (Ct) values with the RPL14, GAPDH, or
HPRT1 (Table 1) control gene Ct, and analysis was car-
ried out with the 2−ΔΔCT method, as reported [7].
ELISA immunoassays
ELISA was used to measure the culture medium concen-
tration of TNF-α (#88-7324-88, eBioscience, San Diego,
CA, USA) and PGE2 (#900-001, Assay Designs, Ann
Arbor, MI, USA).
Nitrite assay
An indirect assessment of nitric oxide (NO) production
was obtained by measuring NO decomposition products
using the spectrophotometric assay based on the Griess
reagent (1% sulfanilamide, 0.1% N-(1-naphthyl)-ethyl-
enediamine dihydrochloride, and 5% phosphoric acid)
[23]. Briefly, 50 μL of culture medium was collected
48 h after LPS treatment (100 ng/mL) in the presence of
either the EP2 antagonist (PF 04418948, 1 μM) or the
corresponding vehicle. Samples were incubated with
equal volumes of Griess reagent for 10 min at room
temperature. Optical density at 540 nm was determined
using a microplate reader (Multiskan spectrum, Thermo
Scientific, Waltham, MA, USA). Nitrite concentration
was determined using a sodium nitrite standard curve.
Statistical analyses
Comparison between two groups was carried out with
the t test or the non-parametric Mann-Whitney test.
One-way ANOVA or the Kruskal-Wallis test were used
for multiple group comparisons, as appropriate, followed
by the post hoc Bonferroni or Dunn test, respectively.
Repeated measures design was applied when appropri-
ate. Two-way ANOVA was used for grouped analyses.
Statistical analyses were carried out using GraphPad
software.
Results
COX-2 mediates the production of PGE2 in glial cells
exposed to LPS
LPS induces the production and release of PGE2 in glial
cells [7]. The PGE2 concentration in the culture medium
of astrocytes increased from basal levels of 0.9 ± 0.3 nM
to 4.8 ± 3.1 nM (mean ± SD, in 11 independent experi-
ments) 8 hours after LPS exposure, as assessed by ELISA
assays. However, COX-2-deficient astrocytes do not pro-
duce PGE2 after LPS, as we previously reported [7]. Also,
PGE2 production was completely abrogated by a range
of COX-2 inhibitors (Fig. 1a, b). Notably, the compound
dimethyl-celecoxib (DMC), an analog of celecoxib that
does not have inhibitory effects on COX-2, also
Table 1 List of primer sequences for mouse PCR
Primer sequence 5′→3′ Accession no. Amplicon length (bp) Region
SYBR green
TNF-α (Tnfa) F: GGGGCCACCACGCTCTTCTGTC NM_013693 155 Exon 1
R: TGGGCTACGGGCTTGTCACTCG Exon 3
Glucose-6P-dehydrogenase (G6pd) F: CACAGTGGACGACATCCGAAA NM_008062.2 103 Exon 4
R: AGCTACATAGGAATTACGGGCAA Exon 5
iNOS (Nos2) F: CAGCTGGGCTGTACAAACCTT NM_010927 95 Exon 17
R: CATTGGAAGTGAAGCGTTTCG Exon 18
VEGFA (Vegfa) F: ATCTTCAAGCCGTCCTGTGTGC NM_001025257.3 223 Exon 3
R: TTGGCTTGTCACATTTTTCTGG Exon 5/6
rpl14 F: GGCTTTAGTGGATGGACCCT NM_025974 143 Exon 3
R: ATTGATATCCGCCTTCTCCC Exon 4
ID Assay Accession no. Amplicon length (bp) Exon boundary
Taqman probes
EP1 (Ptger1) Mm00443098_g1 NM_013641.2 85 Exon 2–3
EP2 (Ptger2) Mm00436051_m1 NM_008964.4 73 Exon 1–2
EP3 (Ptger3) Mm01316856_m1 NM_011196.2 79 Exon 1–2
EP4 (Ptger4) Mm00436053_m1 NM_001136079.2 70 Exon 2–3
NM_008965.2
NOX2 (Cybb) Mm01287743_m1 NM_007807.5 63 Exon 12–13
gapdh Mm99999915_g1 NM_001289726.1 107 Exon 2–3
NM_008084.3
hprt1 Mm00446968_m1 NM_013556.2 65 Exon 6–7
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prevented the increase in PGE2 concentration after LPS
(Fig. 1a, b), possibly due to its described inhibitory ef-
fects on microsomal PGE synthase-1 (mPGES-1) [24].
The potent effect of NS-398 was further validated in
additional astroglia cultures (Fig. 1c) and was chosen to
study COX-2 inhibition in purified microglia cultures.
LPS-induced PGE2 in microglia (Fig. 1d) was also com-
pletely abrogated by the COX-2 inhibitor NS-398
(Fig. 1e). Altogether, the results showed that PGE2 pro-
duction in response to LPS was mediated by the activity
of induced COX-2 in glial cells.
PGE2 attenuates the production of TNF-α induced by LPS
We then interrogated whether PGE2 could modulate
the LPS-induced expression of tumor necrosis factor-
α (TNF-α) (Fig. 2a, b). Treatment with exogenous
PGE2 (1.4–11.3 nM) 30 min before LPS dose-
dependently reduced the production of TNF-α mes-
senger RNA (mRNA) and the release of TNF-α to the
culture medium of astroglial (Fig. 2c, d) and microglial
(Fig. 2e, f ) cells.
Naïve microglial cells express EP4 and EP2 receptors
PGE2 induces selective responses depending on binding
to four membrane receptors EP1-4, which trigger the ac-
tivation of different intracellular signaling pathways.
Thus, we examined the expression of EP receptor
mRNA in our cultured astroglial and microglial cells.
Naïve microglial cells predominantly expressed EP4 and
to a lower extent EP2, whereas the level of expression of
EP1 and EP3 was very low in these cells (Fig. 3a). In
contrast, astrocytes showed similar levels of expression
of all EP1-4 receptors with small differences (EP4 >
EP1 > EP3 > EP2), and the levels of EP4 and EP2 mRNA
were significantly lower than those in microglia (Fig. 3a).
We then used EP antagonists to identify the EP recep-
tors functionally involved in the effect of PGE2 reducing
the induction of TNF-α 8 h after LPS in microglia. The
EP4 antagonist abrogated the PGE2-mediated reduction
of LPS-induced TNF-α mRNA (Fig. 3b) and protein
(Fig. 3c). However, EP1, EP2, or EP3 antagonists did not
prevent the effect of PGE2 (Fig. 3b, c). We concluded
that EP4 mediated the effect of PGE2 reducing LPS-
induced TNF-α. In the absence of exogenous PGE2
treatment, the EP4 receptor antagonist also increased
the expression of TNF-α mRNA (Fig. 3d) and protein
(Fig. 3e) induced by LPS, suggesting that the natural
production of PGE2 after LPS treatment down-regulated
the expression of TNF-α via EP4. Accordingly, treatment
with an EP4 agonist strongly reduced LPS-induced
TNF-α (Fig. 3f ). The EP2 agonist butaprost also reduced
LPS-induced TNF-α mRNA (Fig. 3g), showing that acti-
vation of EP4 or EP2 receptors exert anti-inflammatory
effects in naïve microglial cells. However, antagonizing
Fig. 1 Cox-2 mediates LPS-induced PGE2 in astroglial and microglial cells. Concentration of PGE2 in the culture medium of astrocytes (a–c) and
microglia (d, e), as determined by ELISA. a, b Reduction of LPS-induced PGE2 in the presence of various COX-2 inhibitors: NS-398 (3 μM),
CAY10404 (10 nM), SC-791 (10 nM), celecoxib (10 μM), and the celecoxib analog DMC (10 μM), which does not inhibit COX-2 but interferes with
mPGES-1 activity, 4 (a) and 8 h (b) after LPS exposure (n = 3–9 in two independent experiments). c The potent effect of NS-398 was validated in
additional astroglia cultures 4 h after LPS (n = 3–4 replicates in three independent cultures). d Time-dependent production of PGE2 in microglia
(n = 3–12 in three independent cultures). e NS-398 (3 μM) completely abrogates LPS-induced PGE2 production in microglia (n = 3–6 in two
independent experiments). *p <0.05, **p < 0.01, ***p < 0.001 vs. control; &p < 0.05, &&p < 0.01, &&&p < 0.001 vs. LPS
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EP2 did not significantly increase LPS-induced TNF-α
(Fig. 3d, e) suggesting that the anti-inflammatory action
of LPS-induced PGE2 occurred via EP4, in agreement
with the higher affinity of EP4 than EP2 for PGE2 [25].
LPS down-regulates EP4 and up-regulates EP2 expression
during microglial activation
We then examined whether LPS altered the expression
of the EP receptors during the course of microglial ac-
tivation. Notably, LPS significantly increased the ex-
pression of EP2 mRNA at 8 h, whereas it strongly
down-regulated the expression of EP4 mRNA (Fig. 4a, b).
The effects of LPS changing the level of expression
of EP2 and EP4 receptor mRNA were larger in
microglia than astroglia (Fig. 4a, b). In agreement to
the mRNA changes, 24-h LPS reduced the microglial
EP4 immunoreactivity (Fig. 4c), whereas strong EP2
immunoreactivity was detected (Fig. 4d). Western
blotting revealed a significant increase in EP2 protein
expression after LPS in microglia and macrophages
(Fig. 4e–g). Furthermore, immunofluorescence showed
nuclear/peri-nuclear EP2 immunoreactivity after clas-
sical microglial activation (Fig. 4d). To validate this
finding, we obtained nuclear extracts of macrophages
under control conditions and 24 h after LPS expos-
ure. EP2 expression in the nuclear fraction was de-
tected after LPS (Fig. 4h). Therefore, the cellular
machinery to respond to PGE2 changed from naïve to
primed cells, since the first predominantly expressed
EP4, and to a lower extent EP2, whereas the latter
mainly expressed EP2 that was prominent in nuclear/
peri-nuclear zones.
Fig. 2 PGE2 attenuates the induction of TNF-α by LPS. The expression of TNF-α in astrocytes (a–d) and microglia (e, f) was studied by RT-PCR and
ELISA 4 and 8 h after LPS exposure. a, b LPS induced the expression of TNF-α mRNA (n = 4 replicates per time point in three independent
experiments) (a) and protein in the culture medium (n = 3–5 replicates in three independent experiments) (b). c, d Treatment with PGE2
30 min before LPS reduces, in a dose-dependent manner (1.4–11.3 nM), the induction of TNF-α mRNA (c), and protein (d) (n = 3 replicates
in three independent experiments). e, f In pure microglia cultures, treatment with PGE2 (11.3 nM) also reduced TNF-α mRNA expression
(n = 3–6 replicates in three independent experiments) (e) and protein (n = 3–6 replicates in four independent experiments) (f) at 4 h.
**p < 0.01, ***p < 0.001 vs. control; &p < 0.05, &&p < 0.01, &&&p < 0.001 vs. LPS
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EP2 regulates the expression of genes and proteins
involved in metabolism
We then investigated whether EP2 was involved in
classical microglia polarization by studying gene ex-
pression after 24 h in the presence or absence of EP2
antagonist drug. LPS induced the expression of the in-
ducible nitric oxide synthase (iNOS) mRNA (Fig. 5a), a
typical marker of classical macrophage activation.
Previous studies reported that EP2 was involved in
microglia iNOS expression [26, 27]. Accordingly, an-
tagonizing EP2 reduced the expression of LPS-induced
iNOS mRNA (Fig. 5a), whereas the EP2 agonist buta-
prost increased iNOS mRNA expression in naïve
microglia (Fig. 5b). EP2 also showed a trend to reduce
LPS-induced NADPH oxidase NOX2 mRNA (Fig. 5c),
whereas the agonist increased NOX2 expression
(Fig. 5d). Both NOX2 and iNOS enzymatic activities re-
quire NADPH oxidation. NADPH is produced through
the pentose pathway that is involved in classical macro-
phage activation [28]. LPS increased the mRNA expres-
sion of glucose-6-phosphate dehydrogenase (G6PD)
(Fig. 5e), the pentose pathway rate-limiting enzyme for
NADPH production. The EP2 antagonist prevented
this effect (Fig. 5e) whereas the EP2 agonist promoted
G6PD mRNA expression (Fig. 5f ). In addition, EP2
modulated the expression of the pro-angiogenic factor
vascular endothelial growth factor (VEGFA) mRNA
(Fig. 5g, h).
Fig. 3 Relative EP mRNA expression in glial cells. a EP mRNA expression in naïve astroglia and microglia cultures (n = 6–7 in three independent
cultures for each cell type). For comparative purposes, the level of mRNA for each EP and cell type is expressed as fold versus mean EP1 mRNA
levels in astroglia. EP4 and to a lower extent EP2 expression is comparatively higher than EP1 and EP3 in naïve microglia and is higher in microglia
than astroglia (**p < 0.01, ***p < 0.001). b–g The effect of EP drug antagonist and agonist on TNF-α mRNA expression (RT-PCR) and TNF-α
concentration in the culture medium (ELISA) is shown for microglia cultures 8 h after LPS in the presence or absence of exogenous PGE2
(11.3 nM) (n = 6–9 in 2–3 independent cultures). EP1 antagonist (5 μM SC 51089), EP2 antagonist (1 μM PF 04418948), EP3 antagonist
(0.5 μM L-798,106), and EP4 antagonist (1 μM GW 627368) were used. b, c The EP4 antagonist abrogates the PGE2-induced reduction of
TNF-α mRNA (b) and protein (c) after LPS. d, e The EP4 antagonist increases TNF-α mRNA (d) and protein (e), as assessed by ELISA in the
culture medium, in cells exposed to LPS in the absence of exogenous treatment with PGE2. f, g Treatment with an EP4 agonist (100 nM
ONO-4819) (f) or an EP2 agonist (1 μM butaprost) (g) reduces LPS-induced TNF-α mRNA. (n = 3–4 independent cultures, three replicates in
each). *p < 0.05, **p < 0.01, ***p < 0.001 vs. LPS, &&&p < 0.001 vs. LPS + PGE2
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At the protein level, LPS increased the expression of
NOX-2 at 24 h in microglia (Fig. 6a) (and also macro-
phages, shown in Additional file 3: Figure S3). The EP2
antagonist reduced LPS-induced NOX-2 in microglia
(Fig. 6b), and similar effects were observed for VEGFA
protein (Fig. 6c, d). Furthermore, the concentration of
nitrites in the culture medium was measured as a surro-
gate marker of iNOS activity and nitric oxide produc-
tion. The EP2 antagonist prevented the increase of the
nitrite concentration induced by LPS at 48 h (Fig. 6e).
Discussion
Inflammation induces the expression of COX-2 leading
to the production of prostanoids that exert complex
pleiotropic and cell type-dependent effects. COX-2 activ-
ity produces PGE2 in glial cells stimulated with LPS, and
PGE2 exerts diverse actions depending on the activation
of EP1–4 receptors. LPS-induced COX-2 expression and
PGE2 production in astroglia and microglia but naïve
microglial cells expressed higher levels of EP4 and EP2
than astrocytes. We then investigated the effects of PGE2
Fig. 4 Effects of LPS on EP4 and EP2 mRNA expression. a, b LPS strongly depresses EP4 mRNA expression versus naïve cells, whereas it increases EP2
mRNA expression (n= 6–7 in three independent cultures for each cell type) in microglia (a) and astroglia (b) at 8 h. The level of mRNA for each EP and
cell type is expressed as fold versus the corresponding basal mRNA levels in non-stimulated cells (control). c The intensity of microglia EP4
immunoreactivity is strongly reduced 24 h after LPS exposure (n = 4 in two independent experiments). d Microglia EP2 immunoreactivity is detected in
a peri-nuclear/nuclear localization 24 h after LPS (n = 3 replicates per treatment group in three independent experiments). e Western blotting
shows increased EP2 expression after LPS in microglia and macrophages. f Quantification of EP2 protein expression in control microglia
and 8 and 24 h after LPS, where values (EP2/GAPDH ratio) are expressed as fold versus control (*p < 0.05, n = 3 replicates per time point in
two independent experiments). g Quantification of EP2 protein (EP2/GAPDH ratio) in macrophages (n = 3 replicates in three experiments)
also shows a progressive increase with time after LPS. Data were fit to a sigmoidal equation with non-linear regression analysis (r2 = 0.83). h EP2 is found
in the nuclear fraction of macrophages 24 h after LPS (three different cultures, n= 3 in each culture). Scale bar, 25 μm. **p <0.01, ***p <0.001 vs. control
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acting on EP2 and EP4 in microglia. In these cells,
EP4 and EP2 receptors mediated certain anti-inflam-
matory actions of PGE2 since EP4 and EP2 agonists atten-
uated LPS-induced TNF-α production. However, the anti-
inflammatory effect of PGE2 was mainly mediated through
EP4 since only EP4 antagonists increased the production
of LPS-induced TNF-α. The stronger effect of PGE2 on
EP4 than EP2 was attributable to the comparatively
greater affinity of EP4 for PGE2 [25] and to the higher ex-
pression of EP4 receptor in naïve microglial cells. How-
ever, LPS caused a potent reduction of EP4 expression
while it increased the expression of EP2 at 24 and 48 h,
showing a different regulation of the expression of the
EP2 and EP4 genes. Furthermore, EP2 was detected in the
nuclear fraction after classical microglial activation. Con-
sequently, the response of primed microglial cells to PGE2
changed compared to that of naïve microglia due to differ-
ential EP receptor expression.
Previous reports showed that PGE2 reduces the ex-
pression of certain pro-inflammatory genes in microglia
[19, 29]. EP4 receptor signaling attenuates brain inflam-
mation [18] and exerts inhibitory effects on LPS-
induced NFκB signaling [30]. However, EP4 activation
promotes LPS-induced IL-23 secretion in immature den-
dritic cells and IL-17 production in activated T cells
[31], and exerts pro-tumorigenic actions [32]. Therefore,
modulation of EP4 activation in vivo can potentially
exert benefits by attenuating the degree of innate im-
mune responses in naïve microglia, but its various
actions in different cell types could be detrimental or
beneficial depending on the type and stage of disease.
Likewise, EP2 activation is involved in a variety of phys-
iopathological effects. For instance, PGE2 reduces amyl-
oid β-induced phagocytosis in cultured rat microglia
through its action on EP2 [43, 44]. EP2 regulates inflam-
matory responses in vivo since conditional deletion of
EP2 in macrophages and microglia suppresses inflamma-
tion after systemic LPS administration to mice [45].
Also, EP2 promotes neutrophil recruitment through the
local production of granulocyte colony-stimulating fac-
tor during acute inflammation [46] and mediates disease
progression and inflammation in a model of amyo-
trophic lateral sclerosis [47]. In contrast, several studies
attributed beneficial functions to EP2 since allosteric
modulators of EP2 were protective in experimental
models of excitotoxicity [48], EP2−/− mice showed larger
infarct volumes and worse neurological deficits com-
pared to the wild-type mice after experimental brain is-
chemia [49, 50], and EP2-activation limited the synthesis
of inflammatory mediators in a model of LPS-induced
spinal cord inflammation [13]. Accordingly, in our
study, agonizing EP2 in naïve microglia reduced the ex-
pression of TNF-α induced by exposure to LPS, in a
similar way as EP4 did, but, in the absence of specific
EP2 agonists, PGE2 mainly signaled through EP4. How-
ever, in primed microglia the expression of EP4 was
strongly reduced whereas the expression of EP2 and, to
a lower extent EP3, was up-regulated. While in this
study, we focused on the effects of EP2 and EP4, fur-
ther investigation is needed to find out the role of EP3
in primed microglial cells.
Fig. 5 Involvement of EP2 in the expression of genes related to
classical microglial activation. mRNA expression of iNOS (a, b), NOX2
(c, d), G6PD (e, f), and VEGFA (g, h) in microglia. a, c, e, g LPS
increases mRNA expression at 24 h, and an EP2 antagonist (1 μM PF
04418948) reduces the effect of LPS (three to four independent
experiments). b, d, f, h An EP2 agonist (1 μM butaprost) increases
the mRNA expression of these genes at 8 h (three independent
experiments). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control; &p < 0.05
vs. LPS; #p = 0.06 vs. LPS. “EP2 antag” indicates EP2 antagonist
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The presence of EP2 in peri-nuclear/nuclear locations
suggests that activated microglia had an increased cap-
acity to sense intracellular PGE2 that might signal to the
cell nucleus. In previous studies EP receptors have been
found in the nuclear membrane from where they modu-
late gene transcription [33, 34]. The present results show
that EP2 is involved in the induction of VEGFA, the
prototypical pro-angiogenic factor, and iNOS, which also
modulates angiogenesis through the production of nitric
oxide [35] by classically activated microglia. These
findings agree with the reported reduction of iNOS ex-
pression by EP2 antagonization in the BV-2 microglia
cell line exposed to hypoxia [27] and after genetic dele-
tion of EP2 in microglia exposed to LPS [26]. Induc-
tion of iNOS is a typical hallmark of classical
macrophage activation [36], which involves specific
changes in the metabolic status of the cells [28]. iNOS
catalyzes the production of nitric oxide from L-arginine
using NADPH and oxygen [37]. NADPH is produced
by the pentose monophosphate shunt after oxidation of
glucose-6-phosphate by the rate-limiting enzyme
G6PD, which is an important regulator of the cellular
redox status [38, 39]. In turn, NADPH is oxidized by
NADPH oxidases that generate oxygen reactive species
[40]. Several lines of evidence suggest that G6PD might
regulate iNOS expression [41] and angiogenesis [42].
Microglial activation with LPS increased the mRNA ex-
pression of G6PD and the NADPH oxidase NOX2, and
again, our results point to the involvement of EP2 in
these effects. These findings underscore a role of EP2
regulating metabolic processes participating in classical
microglial activation.
Fig. 6 Effects of EP2 antagonist on LPS-induced protein expression in microglia. a LPS increases the expression of NOX2 protein at 24 h. b This
effect is reduced by the EP2 antagonist (1 μM PF 04418948). c Also, LPS increases VEGFA protein expression and the EP2 antagonist attenuates
this effect (d). e The EP2 antagonist reduces the nitrite production in the microglial culture medium induced by LPS at 48 h, indicating that
EP2 contributes to LPS-induced iNOS activity. The figure illustrates a representative experiment (n = 7–11) out of the three independent experiments.
a, c n = 3–6 in two to four independent experiments; b, d n = 3 obtained in three independent experiments. *p≤ 0.05; **p < 0.01. “EP2 antag’ indicates
EP2 antagonist
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Overall, the current findings suggest that EP4 and EP2
expression in naïve microglia mediates certain anti-
inflammatory actions of PGE2, whereas EP2 expression
in classically activated microglia regulates the expression
of iNOS and facilitates a metabolic switch enabling glu-
cose oxidation through the pentose monophosphate
shunt. This pathway is known to generate the NADPH
needed to fuel L-arginine metabolism through iNOS
activity and sustain the activity of NADPH oxidases.
According to these results, we suggest differential re-
sponses of naïve and classically activated microglia to
PGE2 due to differential levels of EP2 and EP4 expres-
sion as well as different subcellular EP2 distribution, as
schematically represented in Fig. 7.
Fig. 7 Schematic representation of the suggested dynamic effects of PGE2 on naïve and primed microglia. a Stimulation of naïve microglia with
LPS activates TLR-4 leading to very rapid transcription of pro-inflammatory genes, including COX-2. COX-2 produces PGE2 and increases the
concentration of PGE2 in the extracellular space. Although selective agonists of EP4 or EP2 exert anti-inflammatory effects, PGE2 mainly induces
anti-inflammatory effects through EP4 in naïve microglia. b During the course of classical microglial activation, EP4 receptor expression is
down-regulated whereas EP2 expression increases and is found in peri-nuclear/nuclear zones enabling responses to high intracellular PGE2.
EP2 favors the induction of iNOS, NOX2, and G6PD. G6PD is involved in metabolic changes promoting glucose utilization through the pentose
pathway that generates NADPH to fuel NO production by iNOS and free radical generation by NOX2. AA arachidonic acid, COX2 cyclooxygenase-2,
G6PD glucose-6-phosphate dehydrogenase, HK hexokinase, TLR-4 Toll-like receptor-4, TF transcription factors, TNF-α tumor necrosis factor-α
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Conclusions
The present results highlight the key role of COX-2 in
PGE2 production after an inflammatory challenge in glial
cells where the COX-2/PGE2 axis exerts diverse effects
mediated by dynamic changes in EP receptor expression.
While PGE2 attenuates the expression of TNF-α by act-
ing on EP4 in naïve microglia, EP4 expression decreases
and EP2 expression increases in classically activated
microglia where it senses high production of PGE2 and
regulates crucial metabolic paths. These results suggest
that adequate targeting of EP receptors in neuroinflam-
matory conditions would benefit from knowledge of the
level of EP receptor expression during the course of the
diseases.
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